Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: A single-center experience

Journal of Dermatological Treatment

Volumn 25, Issue 5, 2014, Pages 419-423

  Fujisawa, Yasuhiro ^a   Nakamura, Yasuhiro ^a   Kawachi, Yasuhiro ^a   Otsuka, Fujio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Angiosarcoma; Docetaxel; Paclitaxel; Surgery

Indexed keywords

DOCETAXEL; MITOXANTRONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS ANGIOSARCOMA; DERMATOMYOSITIS; DISTANT METASTASIS; DRUG EFFICACY; DRUG FATALITY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LIVER METASTASIS; LOCAL EXCISION; LYMPH NODE METASTASIS; MALE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCALP; SKIN TUMOR; SURVIVAL RATE; THIGH; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; WIDE EXCISION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CASE-CONTROL STUDIES; FEMALE; HEMANGIOSARCOMA; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TAXOIDS;

EID: 84883814388     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.754839     Document Type: Article

References (33)

1. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914-1926
2. Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59:1046-1057
3. Brennan MF, Lewis JJ. Diagnosis and management of soft tissue sarcoma. London: Martin Dunitz, 2002
4. Pawlik TM, Paulino AF, Mcginn CJ, Baker LH, Cohen DS, Morris JS, et al. Cutaneous angiosarcoma of the scalp: A multidisciplinary approach. Cancer. 2003;98:1716-1726
5. Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996; 77:2400-2406
6. Willers H, Hug EB, Spiro IJ, Efird JT, Rosenberg AE, Wang CC. Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: Patterns of failure and prognostic factors. Int J Radiat Oncol Biol Phys. 1995;33:585-593
7. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003;CD003293
8. Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2011
9. Fata F, Oreilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037
10. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C. Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma: Report of 9 patients. Cancer. 2007;110:648-651
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247
12. Ankoma-Sey V, Matli M, Chang KB, Lalazar A, Donner DB, Wong L, et al. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene. 1998; 17:115-121
13. Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, Weiss SW, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol. 2000;156:1469-1476
14. Ozawa K, Kondo T, Hori O, Kitao Y, Stern DM, Eisenmenger W, et al. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J Clin Invest. 2001;108:41-50
15. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fibrous tumor. Curr Opin Oncol. 2010;22:351-355
16. Fuller CK, Charlson JA, Dankle SK, Russell TJ. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol. 2010;63:e83-e84
17. De Yao JT, Sun D, Powell AT, Rehmus EH. Scalp angiosarcoma remission with bevacizumab and radiotherapy without surgery: A case report and review of the literature. Sarcoma. 2011;2011:160369
18. McLaughlin ER, Brown LF, Weiss SW, Mulliken JB, Perez-Atayde A, Arbiser JL. VEGF and its receptors are expressed in a pediatric angiosarcoma in a patient with Aicardi's syndrome. J Invest Dermatol. 2000;114:1209-1210
19. Espat NJ, Lewis JJ, Woodruff JM, Antonescu C, Xia J, Leung D, et al. Confirmed angiosarcoma: Prognostic factors and outcome in 50 prospectively followed patients. Sarcoma. 2000;4:173-177
20. Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009;16:2502-2509
21. Steward WP, Verweij J, Somers R, Blackledge G, Clavel M, Van Oosterom AT, et al. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: Preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. J Cancer Res Clin Oncol. 1991;117:S193-S197
22. Sparano JA. Taxanes for breast cancer: An evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1: 32-40; discussion 1-2
23. Novello S, Le Chevalier T. European perspectives on paclitaxel/ platinum-based therapy for advanced non-small cell lung cancer. Semin Oncol. 2001;28:3-9
24. Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69-78
25. Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol. 2008;108:58-62
26. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843-1849
27. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57:81-86
28. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998;16:1112-1121
29. Nakamura Y, Hori E, Furuta J, Furuta J, Kawachi Y, Otsuka F. Complete long-term response of angiosarcoma of the scalp with cervical lymph node metastases treated with a combination of weekly and monthly docetaxel. Br J Dermatol. 2010;163:1357-1358
30. Sumikawa Y, Inui S, Nishimura Y, Morita E, Kurachi K. Long-term metronomic docetaxel chemotherapy for inoperative angiosarcoma of the scalp. J Dermatol. 2011;38:393-395
31. Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21:270-276
32. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther. 2010;10:249-260
33. Penel N, Marreaud S, Robin YM, Hohenberger P. Angiosarcoma: State of the art and perspectives. Crit Rev Oncol Hematol. 2011;80: 257-263